GLSI — Greenwich LifeSciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1799788 ·
Last close
$16.53
Market Cap
$242.63M
52W High
$34.10
52W Low
$7.78
ADV30
126,798
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,021,645 | -3,948,675 | 8,876,353 | 8,876,353 | 5,759,396 |
| Mar 2026 | 0 | — | -5,725,754 | -5,657,137 | 10,505,435 | 10,505,435 | 5,235,229 |
| Dec 2025 | 0 | — | -7,944,991 | -7,922,733 | 6,178,021 | 6,178,021 | 5,824,804 |
| Sep 2025 | 0 | — | -4,174,642 | -4,151,845 | 3,806,978 | 3,806,978 | 1,622,001 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,781,497
Investing CF
—
Financing CF
$20,536,973
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.20
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-92,794,143
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,891,340
Pretax Income TTM
$-21,756,993
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,447,918 | -19,358,218 | 6,178,021 | 5,824,804 | 353,217 | -9,913,453 |
| Dec 2024 | 0 | -17,637,227 | -17,414,219 | 4,093,769 | 3,185,143 | 908,626 | -7,266,543 |
| Dec 2023 | 0 | -9,327,866 | -8,891,803 | 6,994,815 | 294,406 | 6,700,409 | -6,478,602 |
| Dec 2022 | 0 | -8,040,254 | -7,825,237 | 13,477,029 | 262,905 | 13,214,124 | -6,200,027 |
TTM Snapshot
Revenues TTM
$134,347
NetIncome TTM
$-21,756,993
OpCashFlow TTM
—
Assets (Latest)
$10,505,435
Forward EPS
$-0.82
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $244.15M | $6.45 | — |
| MGNX | MACROGENICS INC | $238.24M | $3.74 | — |
| QTTB | Q32 Bio Inc. | $248.28M | $8.34 | — |
| KROS | Keros Therapeutics, Inc. | $236.93M | $11.95 | — |
| ACIU | AC Immune SA | $248.57M | $2.50 | — |
News headlines (Yahoo Finance, 1h cache)
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
2026-07-20 10:00 · Yahoo
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
2026-07-16 11:30 · Yahoo
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01
2026-07-09 10:00 · Yahoo
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial
2026-06-01 11:48 · Yahoo
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026
2026-06-01 12:15 · Yahoo
Greenwich LifeSciences Provides Update Regarding Form 10-K Filing
2026-06-01 10:00 · Yahoo
Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing
2026-05-22 20:30 · Yahoo
Greenwich LifeSciences Provides Update on Financing Strategy
2026-04-14 10:00 · Yahoo
Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026
2026-04-23 10:00 · Yahoo
Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026
2026-04-20 10:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.